Labiotech

Beyond Biotech - the podcast from Labiotech

News EN ↓ 223 episodes

Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry. A new podcast episode is available every Friday. The host is Dylan Kissane.

Be sure to visit the podcast's website and support the creator: podcast.labiotech.eu

Author

Labiotech

Category

News

Podcast website

podcast.labiotech.eu

Latest episode

Nov 13, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

Inside Arbor’s CNS pipeline and next-generation gene editing 13.11.2026

Gene editing has spent the last decade proving what's possible in the lab. The next decade is about proving it can reach the patients who need it most, from ultra-rare liver diseases to conditions like ALS, where no truly effective treatments exist today.  Arbor Biotechnologies is one of the companies pushing that frontier, built on a diverse toolbox of editing technologies that goes beyond t...

How to turn a BIO-Europe meeting into a lasting partnership 06.11.2026

Partnering season is here. As the biopharma community heads to BIO-Europe and the busy end-of-year conference calendar, the question isn’t just who you meet, but how you make those meetings count. In this special episode of Beyond Biotech, we’re talking about the small details that make a big difference at global conferences. Joining me is Shashi Koduru, Senior Director of Business Development at...

Genprex bets on a one-time gene therapy for diabetes (Part 3 of 3) 30.10.2026

Welcome to a special three-part series called 'The Metabolic Moment'. In just a few years, GLP-1 drugs have become a phenomenon. They’ve transformed how we treat diabetes and obesity, created one of the biggest markets in pharma, and sparked a cultural conversation that reaches far beyond the clinic. Now that market is shifting. Cheaper alternatives are coming, new mechanisms are enterin...

GLP-1 muscle loss: the next battleground in obesity treatment (Part 2 of 3) 23.10.2026

Welcome to a special three-part series called 'The Metabolic Moment'. In just a few years, GLP-1 drugs have become a phenomenon. They’ve transformed how we treat diabetes and obesity, created one of the biggest markets in pharma, and sparked a cultural conversation that reaches far beyond the clinic. Now that market is shifting. Cheaper alternatives are coming, new mechanisms are enterin...

The next big shake-up in the GLP-1 market? (Part 1 of 3) 16.10.2026

Welcome to a special three-part series called 'The Metabolic Moment'. In just a few years, GLP-1 drugs have become a phenomenon. They’ve transformed how we treat diabetes and obesity, created one of the biggest markets in pharma, and sparked a cultural conversation that reaches far beyond the clinic. Now that market is shifting. Cheaper alternatives are coming, new mechanisms are enterin...

Saudi Arabia's biotech momentum: inside RGMBS 2026 09.10.2026

Saudi Arabia has spent the last four years building one of the most ambitious biotech gatherings in the region: the Riyadh Global Medical Biotechnology Summit . This September, the fourth edition brought together delegations from more than 57 countries and over 200 speakers, closing with more than 40 agreements and initiatives worth over SAR5 billion. From gene editing and genomics to AI-driven dr...

How Flagship's Valo is reshaping AI drug discovery with human data 02.10.2026

AI has been one of the biggest buzzwords in biotech for years now — but for all the technological progress, actual R&D productivity gains have been hard to find, and the cost of developing a new drug keeps climbing. My guest today believes that's because AI alone was never going to be the answer. Valo , a biotech founded by Flagship Pioneering, is betting on a different approach: combinin...

Theialife’s race to bring a childhood myopia treatment to market 25.09.2026

By 2050, nearly half the world's population is expected to be myopic, with around a billion people projected to progress to high myopia — a leading cause of irreversible vision loss later in life. Children face a narrow window in which to intervene, while the eye is still growing, before those structural changes become permanent. Yet despite the scale of the problem, there is still no FDA-app...

The best biotech conversations you missed this summer 18.09.2026

Summer is a busy time for everyone, guests and listeners alike, so today we're taking stock. This is our Summer Recap — a clips episode pulling together the best moments from conversations you might have missed over the past few months. We'll hear from Randy Teel of Arvinas and Per Lundin of Evox on two very different ways of getting drugs to the brain, and Laurent Lévy of Nanobiotix on...

Rewriting the rules of genetic medicine with tRNA therapeutics 11.09.2026

Most genetic medicines are built to treat one gene, one mutation, one disease at a time. That's true even for the newest modalities — gene therapy, gene editing, mRNA — each still has to be engineered disease by disease. Alltrna is testing a different idea: that the real target isn't the gene, but the process of translation itself, where genetic instructions become protein. The company&a...

How Evox Therapeutics is targeting CNS diseases with exosomes 04.09.2026

Gene therapy has largely stayed out of the brain, and the blood-brain barrier has been the reason why — it protects the brain from harm, but it also blocks most advanced medicines from ever reaching it. That's now beginning to change. The recent FDA approval of a brain-penetrant enzyme therapy for Hunter syndrome showed that biologics can cross that barrier and work. The next question is whet...

BIOSPAIN 2026: partnering, policy, and the rise of Spanish biotech 28.08.2026

Today we’re thrilled to bring you a special episode highlighting one of Europe’s premier biotechnology events: BIOSPAIN 2026. Joining us is Stuart Medina of Asebio, who will take us inside this landmark gathering. For the first time and in response to strong sector demand and growing interest, BIOSPAIN moves to an annual format. Hosted this year in vibrant Bilbao in Spain’s dynamic Basque Country,...

Beyond biology: Nanobiotix's physics-first approach to cancer 21.08.2026

What if the key to beating cancer wasn't a new drug, but a new way of thinking about matter itself? That's the question Laurent Lévy asked when he co-founded Nanobiotix over twenty years ago — and it's a question that is now producing some genuinely compelling answers in the clinic. Nanobiotix is a Paris-based biotech pioneering what they call physics-based nanomedicine. Their lead...

How Cancer Research Horizons is building the future of childhood cancer medicines 14.08.2026

Cancer is still the leading cause of death by disease in children and young people — yet in the last twenty years, only a handful of drugs have been approved specifically to treat it. Most paediatric cancer treatments are simply adult drugs, repurposed, often at real long-term cost to the children who survive. Today's guest is working to change that, and much more besides.  Tony Hickson is Ch...

Why Western pharma is sleeping on China's circular RNA revolution 07.08.2026

RNA therapeutics has had its defining moments. Antisense oligonucleotides. siRNA. And then, of course, mRNA — which went from a niche academic curiosity to the backbone of a global vaccine program in a matter of months. The next chapter may be circular RNA. CircRNA is more stable than linear mRNA, longer-lasting in the body, and potentially re-dosable. And one company has quietly built what may be...

Gain Therapeutics: a first-in-class, disease-modifying therapy for Parkinson's 31.07.2026

Today we welcome Gene Mack, President and CEO of Gain Therapeutics.  With over 25 years of experience spanning biochemistry, Wall Street analysis, and biotech leadership, Gene brings deep expertise in capital markets, strategy, and drug development. He joined Gain in 2024 and stepped into the CEO role in early 2025. Gain Therapeutics is a clinical-stage biotech pioneering next-generation allosteri...

This nonprofit is building the ecosystem to cure epidermolysis bullosa 24.07.2026

Epidermolysis bullosa, or EB, is one of those diseases that stops you in your tracks the moment you understand it. Skin so fragile that the gentlest touch can cause blisters and open wounds. No cure. And for most of its history, very little serious drug development attention. That's where today's guest comes in.  Martin Steiner is Managing Director of DEBRA Research, a non-profit organiz...

How BIO-Europe is expanding beyond dealmaking in 2026 17.07.2026

The life sciences industry has always had one great meeting place, a few days in November where the deals get done, the partnerships form, and the direction of the industry quietly shifts. For more than three decades, that place has been BIO-Europe . But this year, something is changing.  BIO-Europe has always been the destination for BD professionals and dealmakers. In 2026, it's expanding —...

Turning cancer cell dependencies into targeted therapies 10.07.2026

Today I’m delighted to welcome Andy Parker, CEO of Step Pharma . With over 25 years of experience across AstraZeneca, Shire, Zealand Pharma, and venture capital, Andy has led Step Pharma since 2019. The company is pioneering a targeted approach to cancer and blood disorders by inhibiting the enzyme CTPS1. Their lead candidate, dencatistat, blocks this pathway that certain cancer cells and activate...

The first PROTAC is here. What comes next in protein degradation? 03.07.2026

Today I'm sitting down with Randy Teel, Ph. D., President and CEO of Arvinas, a clinical-stage biotech based in New Haven, Connecticut, that is doing something genuinely new in medicine. Arvinas is pioneering a technology called PROTAC protein degradation. It's a platform that doesn't just block disease-causing proteins, but eliminates them entirely using the body's own disposa...

De-risking neurology drug development with better mouse models 26.06.2026

Today we welcome Brandy Wilkinson, CEO of GemPharmatech , and Rikki Feng, the company’s Neuroscience Pipeline Leader.  Our discussion focuses on a persistent challenge in drug development: neurology’s stubbornly high clinical failure rates. GemPharmatech is tackling this head-on with proprietary models for Alzheimer’s, Parkinson’s, and blood-brain barrier transport that better mirror human disease...

BIO International Convention 2026: practical advice from former Evotec CEO Werner Lanthaler 19.06.2026

This week we preview the BIO International Convention, starting next week in San Diego. This is the key partnering event of the year where biotechs connect with pharmaceutical companies and investors in partnering meetings, all to advance and fund innovative therapies. My guest is Werner Lanthaler, Founder and CEO of WLAN Holding. Werner spent 15 years as CEO of Evotec SE, scaling the company from...

Advancing corticosteroids and hormonal therapies for supply and scale 12.06.2026

Today we’re diving into the world of corticosteroids and hormonal therapies — essential APIs that treat everything from asthma and autoimmune diseases to diabetes and endocrine disorders. These molecules may be decades old, but their manufacturing remains highly complex and critical to patients worldwide. Our guest is Olivier Roux, a Senior Director at Curia. He shares how Curia partners with both...

Episode 200 Special: Joachim Eeckhout on building Labiotech and the future of biotech media 05.06.2026

Welcome to episode 200! Today I’m delighted to welcome back a very special guest: Joachim Eeckhout, the co-founder of Labiotech, co-owner of Knowbio, and founder of The Science Marketer. Joachim tells the Labiotech story, one of vision, persistence, and a deep belief that the European life-sciences sector deserved better storytelling. We go back to the very beginning with someone who was there: th...

World MS Day Special: Immunic reveals new hope for progressive MS 29.05.2026

Today we welcome Dr. Daniel Vitt, CEO of Immunic Therapeutics .  With World MS Day being tomorrow, the 30th of May, this is the perfect moment to focus on multiple sclerosis — a disease that affects nearly three million people worldwide and still leaves many patients searching for better options. In today’s episode Daniel shares his own journey into biotechnology, walk us through what life with MS...

Listen to the Beyond Biotech - the podcast from Labiotech podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.